메뉴 건너뛰기




Volumn 10, Issue 11, 2012, Pages 1391-1398

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer

(19)  Fury, Matthew G a   Sherman, Eric a   Lisa, Donna a   Agarwal, Neeraj b   Algazy, Kenneth c   Brockstein, Bruce d   Langer, Corey c   Lim, Dean e   Mehra, Ranee f   Rajan, Sandeep K g   Korte, Susan a   Lipson, Brynna a   Yunus, Furhan h   Tanvetyanon, Tawee i   Smith Marrone, Stephanie a   Ng, Kenneth a   Xiao, Han a   Haque, Sofia a   Pfister, David G a  


Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB;

EID: 84871414072     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0144     Document Type: Article
Times cited : (33)

References (22)
  • 1
    • 0037115674 scopus 로고    scopus 로고
    • Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma
    • Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-7356. (Pubitemid 36025259)
    • (2002) Cancer Research , vol.62 , Issue.24 , pp. 7350-7356
    • Ang, K.K.1    Berkey, B.A.2    Tu, X.3    Zhang, H.-Z.4    Katz, R.5    Hammond, E.H.6    Fu, K.K.7    Milas, L.8
  • 3
    • 78649469283 scopus 로고    scopus 로고
    • Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck
    • Sharafinski ME, Ferris RL, Ferrone S, Grandis JR. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 2010;32:1412-1421.
    • (2010) Head Neck , vol.32 , pp. 1412-1421
    • Sharafinski, M.E.1    Ferris, R.L.2    Ferrone, S.3    Grandis, J.R.4
  • 4
    • 17444403242 scopus 로고    scopus 로고
    • Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
    • DOI 10.1016/j.ccr.2005.03.003
    • Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-311. (Pubitemid 40544648)
    • (2005) Cancer Cell , vol.7 , Issue.4 , pp. 301-311
    • Li, S.1    Schmitz, K.R.2    Jeffrey, P.D.3    Wiltzius, J.J.W.4    Kussie, P.5    Ferguson, K.M.6
  • 5
    • 79955083789 scopus 로고    scopus 로고
    • Cetuximab in the treatment of squamous cell carcinoma of the head and neck
    • Specenier P, Vermorken JB. Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 2011;11:511-524.
    • (2011) Expert Rev Anticancer Ther , vol.11 , pp. 511-524
    • Specenier, P.1    Vermorken, J.B.2
  • 6
    • 23844523253 scopus 로고    scopus 로고
    • Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
    • Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-5577.
    • (2005) J Clin Oncol , vol.23 , pp. 5568-5577
    • Baselga, J.1    Trigo, J.M.2    Bourhis, J.3
  • 7
    • 34250180582 scopus 로고    scopus 로고
    • Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
    • DOI 10.1200/JCO.2006.06.7447
    • Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based chemotherapy. J Clin Oncol 2007;25:2171-2177. (Pubitemid 46954639)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.16 , pp. 2171-2177
    • Vermorken, J.B.1    Trigo, J.2    Hitt, R.3    Koralewski, P.4    Diaz-Rubio, E.5    Rolland, F.6    Knecht, R.7    Amellal, N.8    Schueler, A.9    Baselga, J.10
  • 8
    • 33144461661 scopus 로고    scopus 로고
    • Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group Study
    • DOI 10.1200/JCO.2005.02.4646
    • Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer. J Clin Oncol 2005;23:8646-8654. (Pubitemid 46211507)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.34 , pp. 8646-8654
    • Burtness, B.1    Goldwasser, M.A.2    Flood, W.3    Mattar, B.4    Forastiere, A.A.5
  • 9
    • 51649085865 scopus 로고    scopus 로고
    • Platinum-based chemotherapy plus cetuximab in head and neck cancer
    • Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl J Med 2008;359:1116-1127.
    • (2008) New Engl J Med , vol.359 , pp. 1116-1127
    • Vermorken, J.B.1    Mesia, R.2    Rivera, F.3
  • 12
    • 77954306356 scopus 로고    scopus 로고
    • Cetuximab administered once every second week to patients with metastatic colorectal cancer: A two-part pharmacokinetic/pharmacodynamic phase i dose escalation cetuximab
    • Tabernero J, Ciardiello F, Rivera F, et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose escalation cetuximab. Ann Oncol 2010;21:1537-1545.
    • (2010) Ann Oncol , vol.21 , pp. 1537-1545
    • Tabernero, J.1    Ciardiello, F.2    Rivera, F.3
  • 13
    • 40349087139 scopus 로고    scopus 로고
    • Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: An effective, more convenient alternative to weekly administration?
    • DOI 10.1634/theoncologist.2007-0201
    • Tabernero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 2008;13:113-119. (Pubitemid 351342574)
    • (2008) Oncologist , vol.13 , Issue.2 , pp. 113-119
    • Tabernero, J.1    Pfeiffer, P.2    Cervantes, A.3
  • 14
    • 77949887855 scopus 로고    scopus 로고
    • Pharmacogenomic and pharmacogenetic studies of cetuximab in metastatic colorectal cancer: Biomarker analysis of phase i dose escalation study
    • Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmacogenetic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of phase I dose escalation study. J Clin Oncol 2010;28:1181-1189.
    • (2010) J Clin Oncol , vol.28 , pp. 1181-1189
    • Tabernero, J.1    Cervantes, A.2    Rivera, F.3
  • 15
    • 48349134539 scopus 로고    scopus 로고
    • Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: Results of a phase II single institution trial
    • Martin-Martorelli P, Rosello S, Rodriguez-Braun E, et al. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer 2008;99:455-458.
    • (2008) Br J Cancer , vol.99 , pp. 455-458
    • Martin-Martorelli, P.1    Rosello, S.2    Rodriguez-Braun, E.3
  • 16
    • 44849083804 scopus 로고    scopus 로고
    • Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil
    • DOI 10.1093/annonc/mdn020
    • Pfeiffer P, Nielsen D, Bjerregaard J, et al. Biweekly cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin, and 5-fluorouracil. Ann Oncol 2008;19:1141-1145. (Pubitemid 351796340)
    • (2008) Annals of Oncology , vol.19 , Issue.6 , pp. 1141-1145
    • Pfeiffer, P.1    Nielsen, D.2    Bjerregaard, J.3    Qvortrup, C.4    Yilmaz, M.5    Jensen, B.6
  • 17
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 18
    • 33748131278 scopus 로고    scopus 로고
    • Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    • DOI 10.1200/JCO.2005.05.4577
    • Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2659-2665. (Pubitemid 46622087)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.17 , pp. 2659-2665
    • Cohen, E.E.W.1
  • 19
    • 84655164982 scopus 로고    scopus 로고
    • Feasibility of cetuximab given wtih a simplified schedule every 2 weeks in advanced colorectal cancer: A multicenter, retrospective analysis
    • Bouchahda M, Macarulla T, Liedo G, et al. Feasibility of cetuximab given wtih a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol 2011;28(Suppl 1):S253-258.
    • (2011) Med Oncol , vol.28 , Issue.SUPPL. 1
    • Bouchahda, M.1    Macarulla, T.2    Liedo, G.3
  • 20
    • 55749086974 scopus 로고    scopus 로고
    • Human papillomavirus in HNSCC: Recognition of a distinct disease type
    • Vidal L, Gillison ML. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin N Am 2008;22:1125-1142.
    • (2008) Hematol Oncol Clin N Am , vol.22 , pp. 1125-1142
    • Vidal, L.1    Gillison, M.L.2
  • 21
    • 80053916746 scopus 로고    scopus 로고
    • Biweeky cetuximab and irinotecan as second line therapy in patients with gastro-esophageal cancer previously treated with platinum
    • Schoennemann KR, Bjerregaard JK, Hansen TP, et al. Biweeky cetuximab and irinotecan as second line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer 2011;14:219-225.
    • (2011) Gastric Cancer , vol.14 , pp. 219-225
    • Schoennemann, K.R.1    Bjerregaard, J.K.2    Hansen, T.P.3
  • 22
    • 44849083804 scopus 로고    scopus 로고
    • Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil
    • DOI 10.1093/annonc/mdn020
    • Pfeiffer P, Nielsen D, Bjerregaard J, et al. Biweekly cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin, and 5-fluorouracil. Ann Oncol 2008;19:1141-1145. (Pubitemid 351796340)
    • (2008) Annals of Oncology , vol.19 , Issue.6 , pp. 1141-1145
    • Pfeiffer, P.1    Nielsen, D.2    Bjerregaard, J.3    Qvortrup, C.4    Yilmaz, M.5    Jensen, B.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.